Document Detail

Mepolizumab in eosinophilic disorders.
MedLine Citation:
PMID:  21790283     Owner:  NLM     Status:  MEDLINE    
Mepolizumab (Bosatria(®), GlaxoSmithKline) is a biologic agent developed to treat asthma. It represents a humanized monoclonal antibody of IgG1 κ type, which targets human IL-5 and thus prevents its interaction with the α-chain of the IL-5 receptor. To date, it has not been approved for use in any eosinophil-related disorder; however, several studies have suggested some therapeutic benefit across a spectrum of eosinophil-related disorders. This article evaluates the currently available preclinical and clinical studies, and the impact of mepolizumab against a variety of eosinophilic disorders.
J Pablo Abonia; Philip E Putnam
Related Documents :
11317963 - Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycytha...
17015893 - 18f-flt pet in hematologic disorders: a novel technique to analyze the bone marrow comp...
7691773 - Etretinate therapy for psoriasis and other keratinizing disorders: a 10-year retrospect...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of clinical immunology     Volume:  7     ISSN:  1744-8409     ISO Abbreviation:  Expert Rev Clin Immunol     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-07-27     Completed Date:  2011-11-15     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  101271248     Medline TA:  Expert Rev Clin Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  411-7     Citation Subset:  IM    
Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, ML2010, Cincinnati, OH 45229-3039, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / pharmacology,  therapeutic use*
Antibodies, Monoclonal, Humanized
Asthma / drug therapy*,  immunology
Churg-Strauss Syndrome / drug therapy*,  immunology
Clinical Trials as Topic
Drug Evaluation, Preclinical
Eosinophils / drug effects*,  immunology
Hypereosinophilic Syndrome / drug therapy*,  immunology
Interleukin-5 / immunology,  metabolism
Grant Support
R01 DK076893-03S1/DK/NIDDK NIH HHS
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/IL5 protein, human; 0/Interleukin-5; 0/mepolizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An Outbreak of Salmonella Typhimurium 108/170 at a Privately Catered Barbeque at a Sydney Sports Clu...
Next Document:  Budesonide in the treatment of inflammatory bowel disease.